Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy.

Abstract

Chronic diarrhea remains a common condition that affects people infected with human immunodeficiency virus (HIV) despite the widespread use of potent antiretroviral therapy. It is important that providers control this condition, as the persistence of diarrhea affects the quality of life of patients and may contribute to decreased adherence to antiretroviral therapy. Strategies to control diarrhea in patients with HIV infection include switching to a new antiretroviral regimen and/or the use of specific medications to control the diarrhea. This review aims to provide a concise evaluation of a newly approved medication (crofelemer) that has a novel mechanism of action and has received approval for the symptomatic relief of non-infectious diarrhea in adult patients with HIV on anti-retroviral therapy.

• Authors: Jose G Castro, Nafeesa Chin-Beckford
• Journal: Expert review of clinical pharmacology (Expert Rev Clin Pharmacol) Vol. 8 Issue 6 Pg. 683-90 ( 2015) ISSN: 1751-2441 [Electronic] England
• PMID: 26517110 (Publication Type: Journal Article, Review)

Chemical References

• Anti-HIV Agents
• Antidiarrheals
• Proanthocyanidins
• crofelemer

Topics

• Adult
• Anti-HIV Agents (administration & dosage, therapeutic use)
• Antidiarrheals (pharmacology, therapeutic use)
• Chronic Disease
• Diarrhea (drug therapy, etiology)
• HIV Infections (complications, drug therapy)
• Humans
• Medication Adherence
• Proanthocyanidins (pharmacology, therapeutic use)
• Quality of Life